Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity (Details Narrative)

Stockholders’ Equity (Details Narrative) - USD ($)											1 Months Ended	3 Months Ended	12 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Feb. 14, 2023	Feb. 03, 2023	Apr. 01, 2022	Mar. 29, 2022	Mar. 23, 2022	Aug. 20, 2021	Jun. 16, 2021	Jun. 08, 2021	Feb. 24, 2021	Oct. 06, 2020	Jan. 31, 2023	Mar. 25, 2023	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2022
Class of Stock [Line Items]
Common stock, shares authorized													50,000,000	30,000,000	50,000,000
Preferred stock, shares issued													0	0
Preferred stock, shares outstanding													0	0
Proceeds from issuance of stock													$ 6,400,000
Shares issued in private placement, net of transaction costs, value														$ 9,875,550
Repurchase of common stock value													$ 300,000
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of shares, forfeited													68,539	4,000
Number of shares, granted			1,979,818										2,428,285	457,593
Restricted Stock Units (RSUs) [Member] \| Federal, State and Local [Member]
Class of Stock [Line Items]
Number of shares, forfeited													36,145
Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, forfeited													33,489	10,706
Number of shares, granted													187,058	37,500
Restricted Stock [Member] \| Employment Termination [Member]
Class of Stock [Line Items]
Number of shares, forfeited														1,530
Restricted Stock [Member] \| Federal, State and Local [Member]
Class of Stock [Line Items]
Number of shares, forfeited														9,176
Common Stock [Member]
Class of Stock [Line Items]
Shares issued during period														1,321,132
Shares issued in connection with the Purchase Agreement with Lincoln Park													123,609
Shares issued in connection with license agreement													100,000	144,689
Shares issued in private placement, net of transaction costs, value														$ 132
Repurchase of common stock value
Common Stock [Member] \| Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Shares issued during period														14,300
Number of shares, granted														17,800
Director [Member] \| Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, forfeited													18,208
Employees [Member] \| Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, granted								37,500
Consultants [Member]
Class of Stock [Line Items]
Options and warrants granted														180,000
Consultants [Member] \| Restricted Stock [Member]
Class of Stock [Line Items]
Number of shares, granted													59,766
Consultants [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Number of shares, granted														17,800
Aposense, Ltd. [Member]
Class of Stock [Line Items]
Number of repurchase of common stock, shares				100,000
Repurchase of common stock value				$ 300,000
Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Shares issued in connection with the Purchase Agreement with Lincoln Park					123,609								123,609
Number of common stock issued on commitment fees, value					$ 450,000
Reimbursement fees					25,000
Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member] \| Maximum [Member]
Class of Stock [Line Items]
Commitment to purchase common stock					$ 15,000,000.0
Number of common stock shares in regular purchase					25,000
Number of common stock shares exceeding regular purchase					75,000
Daily maximum committed purchase obligations, value					$ 1,250,000
Maximum number of shares sold					3,142,430
Nasdaq's exchange cap percent					19.99%
Beneficial ownership limitation percentage					9.99%
Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member] \| Minimum [Member]
Class of Stock [Line Items]
Minimum closing sale price					$ 1.00
Sales Agreement [Member]
Class of Stock [Line Items]
Proceeds from issuance of stock														$ 174,000
Shares issued during period														21,597
Price per share														$ 8.33
Sales Agreement [Member] \| Maximum [Member]
Class of Stock [Line Items]
Maximum number of shares to be sold at the market offering						$ 30,000,000.0
License Agreement [Member] \| Elion Oncology [Member]
Class of Stock [Line Items]
Shares issued in connection with license agreement										825,000			100,000	100,000
License Agreement [Member] \| Ocuphire Pharma Inc [Member]
Class of Stock [Line Items]
Shares issued in connection with license agreement							44,689
License Agreement [Member] \| Aposense, Ltd. [Member]
Class of Stock [Line Items]
Shares issued in connection with license agreement										625,000
Private Placement [Member]
Class of Stock [Line Items]
Shares issued during period									1,321,132
Gross proceeds from issuance of common stock									$ 10,200,000
Shares issued in private placement, net of transaction costs, value									$ 9,900,000
Private Placement [Member] \| Placement Agent [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock									79,268
Warrants exercise price									$ 9.30
Warrant expiration date									Feb. 16, 2023
Subsequent Event [Member]
Class of Stock [Line Items]
Proceeds from issuance of stock												$ 7,000,000.0
Shares issued during period												8,432,192
Subsequent Event [Member] \| Purchase Agreement [Member] \| Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Proceeds from issuance of stock											$ 54,000
Shares issued during period											50,000
Price per share											$ 1.08
Subsequent Event [Member] \| Sales Agreement [Member] \| Oppenheimer & Co. Inc, [Member]
Class of Stock [Line Items]
Proceeds from issuance of stock		$ 693,000
Shares issued during period		569,648
Price per share		$ 1.22
Subsequent Event [Member] \| Sales Agreement [Member] \| Oppenheimer & Co. Inc, [Member] \| Maximum [Member]
Class of Stock [Line Items]
Maximum number of shares to be sold at the market offering		$ 30,000,000.0
Subsequent Event [Member] \| Securities Purchase Agreement [Member] \| Registered Direct Offering [Member] \| Accredited Investor [Member]
Class of Stock [Line Items]
Proceeds from issuance of stock	$ 5,700,000
Shares issued during period	7,812,544
Price per share	$ 0.80
Gross proceeds from issuance of common stock	$ 6,300,000
Subsequent Event [Member] \| Securities Purchase Agreement [Member] \| Registered Direct Offering [Member] \| Accredited Investor [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Gross proceeds from issuance of common stock	$ 6,300,000